Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation
Fierce Pharma
DECEMBER 19, 2024
In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German cancer biotech it acquired earlier this year. | Novartis confirmed Thursday that its closing down MorphoSys sites in Munich and Boston in a move thats expected to result in around 330 layoffs. The company made the decision in November as it looks to integrate all portfolio activities into Novartis.
Let's personalize your content